Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182476 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
NCT05182476 is a Phase 2 study that was terminated before completion, run by Neurocrine Biosciences. The registered enrollment target is 216 participants.
The verdict
NCT05182476, a Phase 2 study, was terminated before completion, sponsored by Neurocrine Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
Study Summary
Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Luvadaxistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182476
The ClinicalTrials.gov registry entry for NCT05182476 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05182476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05182476 about?
NCT05182476 is a clinical study titled "Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia". Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.
What is the current status of trial NCT05182476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2021-12-07. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT05182476?
The interventions under investigation include: Placebo (DRUG), Luvadaxistat (DRUG).
Who is sponsoring clinical trial NCT05182476?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.